

September 27, 2022

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India

BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India

Dear Sir/Madam,

Subject : <u>Investor Presentation</u> Stock Code : <u>BSE – 539787</u>, <u>NSE – HCG</u>

Ref : <u>Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

We are enclosing herewith the Investor Presentation.

Kindly take this on record.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel Company Secretary & Compliance Officer

Encl: a/a.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



HEALTHCARE GLOBAL ENTERPRISES LIMITED





Safe Harbor



This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from India, the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.


This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.









Largest Pan-India Oncology Hospital Chain




Best-in-class cancer care by adopting globally acclaimed practices and state-of-the-art technology



33+ years of Clinical Excellence






(1) Established centers were operational before 2017; (2) Includes 1 in Kenya. Bhavnagar multispecialty also includes comprehensive cancer care and included in CCC count; (3) CCC – Comprehensive cancer care center, defined as offering surgical, medical and radiation oncology services onsite, along with diagnosis / PET CT as well in some cases; (4) Includes multispecialty beds; (5) New patient registrations in last 5 years in oncology


www.hcgel.com

High Patient Volume driving Oncology Growth in India






Indian Cancer Care Industry (INR bn) – Projected Growth




High Growth Headroom due to Low Population Coverage






Low Early-stage Diagnosis in India ...


...leading to High Mortality to Incidence Ratio



Majority of the Comprehensive Cancer Centers concentrated in Metros...



...but Non-Metros to Grow Faster than Metros mainly driven by Volume Growth (FY19-FY24)




Sources: "List of Cancer Treatment Centers licensed by AERB", aerb.gov.in, Feb 2021; "Population of India as per census 2011", Censusindia.gov.in; Industry reports (1) Top 8 metros include Delhi, Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Pune and Ahmedabad

www.hcgel.com






Cancer requires specialized care available at focused players only, with emphasis on clinical expertise



Dominant Network in Cancer Care with Market Leadership across 13 out of 18 Cities



HCG is committed to provide last mile cancer care across India and is the largest player with >1.6x footprint of CCCs as compared to the next largest player



(1) Market position for private oncology players only (excluding trusts, government hospitals), based on management estimates; (2) FY21 revenue for Tata Memorial Hospital - Mumbai, Apollo Hospitals and Omega Hospitals; FY22 revenue for all others. Note: Oncology share is assumed to be 100% for Tata Memorial and Omega Hospitals. For Apollo Hospitals, only hospital revenue (Healthcare Services) is considered

8

www.hcgel.com






SUCCESSFUL SCALABLE MARKET LEADER IN ALMOST **9 NON-METRO CENTERS WITH ALL NON-METRO CENTERS HIGH-TEEN ROCE NON-METRO MODEL** adding life to years Jaipur 👗 13 12 9 9 Baroda Ranchi FY20 - Q1'23⁽¹⁾ Non-Metro Metro Cuttack Bhavnagar Nashik **N**Vishakhapatnam **Revenue Growth** 20% 18% Gulbarga Ongole Hubli Vijaywada Shimoga **Average EBITDA %** 25% 23% All Non->15% >20% Payor Mix⁽²⁾ > 15% 85% 54% Market Leadership (11) **EBITDA EBITDA** Metro ROCE⁽¹⁾ Top 3 in other Non-metro Centers (2) Centers Margin Margin

Note: Figures for Q1'23; (1) For established centers only; (2) Payor mix for cash, insurance and corporate




One Stop Solution with Superior Clinical Expertise





(1) Cases handled in last 5 years; (2) Total CyberKnife cases performed till date (3) Apollo has only 13 centers providing radiation facilities in a network of 71 hospitals Many Firsts of Cutting-edge Technology Introduction for Integrated Cancer Care






www.hcgel.com


Tumor Board based Treatment Approach for Patients





Tumor Board Approach

Case-specific panel curated involving multiple specialists for planning and implementing **efficient treatment**



www.hcgel.com

Marquee Management Team supported by Experienced Promoters






Madan **Srinivasa Dr. Bharat** Ashutosh Sapna Agarwal Stuti Jain Raj Gore **Deepti Tewari** Sudeep Dey Vineesh Ghei Raghavan Kumar Sampath Gadhavi Head of Head Head HR CEO CIO Head Sales CFO Head-Gujarat Supply Chain Marketing Strategy **Operations** 20+ 25+ 20+ 20+ 20+ 25+ 15+ 15+ 13+ 15+ Apollo Apollo CSC Emirates **V** Fortis **V** Fortis **Fortis** sterling The Specialist (ge) Because life matter Motherhood Health Care) E Kokilaben Dhurubhai Ambani COLUMBIA ASIA **St** Fortis **St** Fortis Every Life Matters GODFREY PHILLIPS New Hires since 2020 Existing Management

Total years of experience

Unique Oncologist Engagement Model to Create and Retain Expert Clinicians



HCG has emerged as a major hub for attracting and developing top clinical talent, with its unique offerings of multi-modality learning and sub-specialization expertise providing very high value proposition





Leveraging Digital Transformation to Reshape Patient and Partner Engagement



KEY DIGITAL TRANSFORMATION IMPERATIVES FOR HCG 2.0



Increasing reach and awareness



nichannel patient engagement



Ecosystem of digital healthcare




Integrated patientlifecycle management



convenience


Digitalized post discharge engagement


Transforming Patient Journey - Optimizing Engagement



Proven Track Record of Sustained Growth








 Expansion mode by setting up new cancer centres till FY19 to achieve large scale

 Demonstrated high growth post Covid across centres




- Strong improvement in profitability
- Subdued in expansion phase due to setting up new centres
- Significant scale benefits; outpacing revenue due to operating leverage

(1) FY21 and H1'22 impacted due to covid-related headwinds

(2) EBITDA, post-corporate expenses. EBITDA for FY20-FY22 is after IND AS 116 adjustments

Improved Performance Leading to Profitability






(2) Includes gain on exceptional items of INR 1,401 mn


High Revenue Growth with Well-diversified Segments






Expansive Geographical Presence⁽¹⁾





Emerging Center Turnaround



- Ramp Up of Emerging Centers: Revenue contribution by Emerging Centers increasing consistently
- **Low Geographical Risk:** Diverse geographical spread reducing revenue concentration and dependence
- Multi-Modality: Revenues spread across modalities reducing concentration risk further
- Not Constrained by Beds: c.74% revenue not dependent on in-patient beds due to heterogenous mix of treatments

Strong Operating Metrics with Significant Capacity Headroom



 \bigcirc

Key Driver	Metric Indicator	% Revenue	Q1'22	Q4'22	Q1'23
# New Registrations ('000)	Lead indicator of Volume Growth; key operating metric tracked by HCG; has correlation to out-patient revenue	20%(1)	14	40% 18	20
Chemo Sessions Administered ('000)	Key indicator for Medical Oncology; procedures are primarily day care oriented with no capacity constraint	35%	23	28 28	31
LINAC - Capacity Utilization ⁽²⁾	Key indicator for Radiation Oncology; availability of LINACs is the only capacity constraint; further augmenting capacity by 20%	20%	53%	60%	68%
In-Patient Bed Occupancy ⁽³⁾	Indicator for Surgical Oncology ; with decreasing ALOS and flexibility to add balance non-operational capacity beds, not a capacity constraint operationally; additional 195 beds available to be made operational	25%	50%	54%	61%

www.hcgel.com

(1) Revenue % for out-patient and others only; (2) Total radiation patients treated stands at c. 5,000 in Q1'23; (3) Total in-patient bed capacity for oncology is 1,372 beds and operational beds is 1,177. This excludes 279 day care beds and 328 multispecialty beds



Visible growth opportunities supported by proven brand-driven play, professional approach and ready capacity

	Demand Driven	 Strong growth across regions aided by market leadership and high incidence growth Existing facilities have significant capacity to support the growth 	
Consistent Growth in Existing Business	Digital Transformation	 Management led initiatives to boost digital presence and integrate end-to-end patient engagement; driving higher growth and better realizations 	Strong business and returns profile with
	International Medical Tourism	 Focus on expanding international presence and increasing revenue share in attractive geographies 	deeper market penetration
 Brownfield / Greenfield Expansion 6 LINACs in pipeline (own + pay per use) over next 1-2 years to augment capacity in high growth regions Ongoing greenfield expansion at Ahmedabad and Bangalore by adding 125 beds cumulatively 			

		At the right inflection point to scale-up through additional business adjacencies	
С	Inorganic Expansion	 Playbook of making smart acquisitions and driving sustained growth post integration - only realistic buyer for standalone cancer hospitals in India; successful track record of acquiring and scaling hospitals 	Potential incremental growth
D	Clinical Trials & Diagnostics ⁽¹⁾	 Very low existing scale with 3-4 years of experience; finalizing business plans for significant expansion Capital adjacent opportunity; high potential to expand EBITDA without significant capex 	


Capital Light

Capital Led

www.hcgel.com


Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion






HCG: Unique Long-term Value Creation Opportunity in Single Specialty Healthcare







Strong Financial Profile with Low Leverage and Reduced Capex Needs









with well capitalized

balance sheet








APPENDIX

Successful Playbook of Smart Acquisitions and Driving Sustained Growth Post Integration



Time tested and highly replicable model of consistent revenue growth and profitability across geographies



(1) HMS (multispecialty) was acquired in 2007 but the comprehensive cancer care unit – HCC was demerged in 2013; (2) Till FY22





THANK YOU





CIN: L15200KA1998PLC023489

For updates and specific queries, please visit

www.hcgoncology.com

or feel free to contact investors@hcgoncology.com

© 2022 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademark of HealthCare Global Enterprises Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation.

This material is being used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.